Figure 3

ADAMTS9-AS1 increased ESC viability by regulating ferroptosis. (A) Cell viability of EESCs was assessed after ADAMTS9-AS1 knockdown using a CCK-8 assay in the presence of the indicated inhibitors (ZVAD-FMK, 10 μM; necrostatin-1, 10 μM; ferrostatin-1, 1 μM; disulfiram, 5 μM; 3-MA, 10 mM). (B) Cell viability of NESCs was assessed after ADAMTS9-AS1 overexpression using a CCK-8 assay in the presence or absence of erastin (10 μM). (C) Cell viability of EESCs was assessed after treatment with the indicated inhibitors (ZVAD-FMK, 10 μM; ferrostatin-1, 1 μM) in the presence or absence of sorafenib (5 μM). p < 0.05, **p < 0.01.